Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2022-04-30 Notice of Dividend Amou…
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Disclosure of other UPSI/material event
Notice of Dividend Amount Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the book closure dates for the purpose of the 37th Annual General Meeting and payment of final dividend for the financial year ended March 31, 2022. It references compliance with SEBI Listing Regulations and the Companies Act. The document is short (3456 characters) and serves as an intimation or announcement rather than containing any financial statements or detailed report content. It specifically informs about book closure and AGM date, which is related to dividend and shareholder meeting logistics. This fits the category of Notice of Dividend Amount (DIV) since it relates to dividend payment and shareholder record dates, rather than the AGM materials themselves or the annual report. Therefore, the best classification is Notice of Dividend Amount (DIV).
2022-04-30 English
Dividend
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges reporting the outcome of a Board Meeting held on April 30, 2022. It includes approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2022, along with audit reports. It also mentions the declaration of an unmodified audit opinion, recommendation of a final dividend subject to shareholder approval, re-appointment of statutory auditors, internal auditors, and secretarial auditors, and scheduling of the 37th Annual General Meeting. The document is an announcement of the Board Meeting outcomes and financial results, not the full financial report itself. The length is about 5208 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a regulatory announcement of financial results and board decisions, not the full Annual Report or Audit Report itself.
2022-04-30 English
Pursuant to Section 91 of the Companies Act, 2013 ('Act'') and applicable Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") ....
Notice of Dividend Amount Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the book closure dates for the purpose of the 37th Annual General Meeting and payment of the final dividend for the financial year ended March 31, 2022. It references compliance with SEBI Listing Regulations and the Companies Act. The content is an announcement about the book closure period and related AGM and dividend payment dates, not the AGM materials themselves or the dividend declaration details. The document length is 3456 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits best as a Notice of Dividend Amount (DIV) since it relates to dividend payment timing and shareholder record dates, but it also closely relates to book closure for AGM and dividend purposes. However, since the primary focus is on book closure and dividend payment timing, the most appropriate classification is Notice of Dividend Amount (DIV).
2022-04-30 English
Pursuant to Regulation 30 of Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'') read with Para B ....
Regulatory Filings
2022-04-30 English
Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2022, subject to approval of the shareholders in ....
Regulatory Filings
2022-04-30 English
Financial Result Updates
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from the Board of Directors of Bliss GVS Pharma Ltd. regarding the outcome of a Board Meeting held on April 30, 2022. It includes approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2022, along with the audit report. It also mentions the declaration of an unmodified audit opinion, recommendation of a final dividend, re-appointment of statutory auditors, internal auditors, and secretarial auditors, and scheduling of the 37th Annual General Meeting. The document is addressed to stock exchanges and references compliance with SEBI regulations. The content is an official announcement of the Board Meeting outcomes and financial results approval, not the full annual report or audit report itself. The document length is about 15,000 characters, but it primarily serves as a formal disclosure of decisions made at the Board Meeting, including financial results and dividend recommendations. Therefore, it fits best as a Regulatory Filing (RNS) because it is a regulatory announcement of the Board Meeting outcome and financial results, not the full Annual Report (10-K) or standalone Audit Report (AR).
2022-04-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.